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Many osteopenic disorders, including a postmenopausal osteoporosis and lytic bone metastasis in breast and prostate cancers, are
linked with a hyperosteoclast activity due to increased receptor activator of nuclear factor kappa-B ligand (RANKL) expression
in osteoblastic/stromal cells. Therefore, inhibition of RANKL-induced osteoclastogenesis and osteoclast-induced bone resorption
is an important approach in controlling pathophysiology of these skeletal diseases. We found that, of seven type I, II, and III
saikosaponins isolated from Bupleurum falcatum, saikosaponins A and D, type I saikosaponins with an allyl oxide linkage between
position 13 and 28 and two carbohydrate chains that are directly attached to the hydroxyl groups in position 3, exhibited the most
potent inhibition on RANKL-induced osteoclast formation at noncytotoxic concentrations. The stereochemistry of the hydroxyl
group at C16 did not affect their activity. Saikosaponins A and D inhibited the formation of resorptive pits by reducing the secreted
levels ofmatrixmetalloproteinase- (MMP-) 2,MMP-9, and cathepsinK inRANKL-induced osteoclasts. Additionally, saikosaponins
A and D inhibited mRNA expression of parathyroid hormone-related protein as well as cell viability and invasion in metastatic
human breast cancer cells. Thus, saikosaponins A and D can serve as a beneficial agent for the prevention and treatment of
osteoporosis and cancer-induced bone loss.
1. Introduction
Bone is a specialized connective tissue composed of both
mineral and organic phases that is exquisitely designed for
its role as the load-bearing structure of a body. Unlike other
durable structures, such as teeth, tendons, and cartilage, bone
is continuously renewed by the process of bone remodeling
in which pockets or trenches of bone are removed from the
surfaces of the trabecular and cortical bone and subsequently
replaced by new bone. The process of bone remodeling
consists of both osteoclastic bone resorption and osteoblastic
bone formation [1]. Under healthy physiological conditions,
activities of osteoclasts and osteoblasts are tightly controlled
by both systemic and local factors, maintaining bone mineral
density and bone microarchitecture. However, an imbalance
in osteoclasts and osteoblasts activities, mostly in favor of
a hyperosteoclast activity, is responsible for pathophysiol-
ogy of several skeletal diseases, including osteoporosis and
metastatic bone diseases [1].
Current medical treatment of osteoporosis and breast
cancer bonemetastasis is anti-bone resorptive agents, includ-
ing bisphosphonates and denosumab [2–4]. Bisphosphonates
and denosumab, a receptor activator of nuclear factor kappa-
B ligand (RANKL) inhibitor, delay time to first skeletal related
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event. However, these drugs do not prevent development of
bone metastasis and also do not prolong survival [4]. Thus,
emerging therapies, including cathepsin K, matrix metallo-
proteinase, or nonreceptor tyrosine kinase Src inhibitors, are
being introduced for prevention and treatment of osteoporo-
sis and cancer bone metastasis. In addition, many medicinal
plants and their active components in traditional Chinese
medicine have been proven to possess efficacy on osteoporo-
sis and cancer and thereby have attracted attention as a source
of new drugs with better potency and safety for prevention
and long-term treatment [5, 6].
Radix bupleuri is an Asian traditional herbal medicine
used either alone or in combination with other ingredients
for treating influenza, fever, inflammatory disorders, infec-
tious diseases, hepatitis, menstrual disorders, and cancer
[7, 8]. Bupleurum species (Umbelliferae) are formally listed
in the Chinese and Japanese pharmacopoeias and in the
WHO monographs of the commonly used 150 medicinal
plants [9, 10]. Saikosaponins, the most abundant triterpene
saponins found in Bupleurum species, have been known
to exhibit a variety of pharmacological activities, includ-
ing immunomodulatory, antioxidant, hepatoprotective, and
estrogen-like activities [11–13]. Saikosaponins B
1
, B
2
, and
D stimulated prostaglandin E
2
release from peritoneal
macrophages and C6 rat glioma cells; however, saikos-
aponins A and C were inhibitory [13–15]. Saikosaponin B
2
induced apoptosis in B16 melanoma cells and saikosaponin
C increased the angiogenic activity of endothelial cells [16,
17]. Saikosaponin A induced apoptosis in human breast and
colon carcinoma cell lines [18, 19]. Saikosaponin D inhibited
proliferation of human undifferentiated thyroid carcinoma
cells [20] and enhanced radiosensitivity of hepatoma cells
[21]. In addition, a recent study reported osteoclast-inhibiting
activity of saikosaponins B
1
and B
2
[22].
In the present study to detect novel compounds with
preventive and therapeutic activity on osteoclast-mediated
bone diseases, we investigated the inhibitory activity of
seven saikosaponins isolated from B. falcatum (Figure 1) on
RANKL-induced osteoclastogenesis of murine bone marrow
macrophages (BMMs). We further determined the effects
of saikosaponins A and D on bone-resorbing proteases
derived fromosteoclasts and the resulting bone resorption. In
addition, we showed their effect on the viability, invasion, and
production of a key osteolytic factor, parathyroid hormone-
related protein (PTHrP), in metastatic breast cancer cells.
2. Materials and Methods
2.1. Chemicals. Saikosaponins A, B
1
, B
2
, B
3
, B
4
, C, and D
isolated from B. falcatum L. were provided by Professor
Kim [23, 24]. The saikosaponins were dissolved in dim-
ethyl sulfoxide (DMSO) and then diluted with culture
medium just before use. Minimum essential medium alpha
(𝛼-MEM), Dulbecco’s modified Eagle’s medium (DMEM),
fetal bovine serum (FBS), Dulbecco’s phosphate buffered
saline (PBS), antibiotic-antimycotic mixture, and 0.25%
trypsin-EDTA were purchased from Gibco BRL (Grand
Island, NY). Histopaque-1083, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), and dimethyl sul-
foxide (DMSO)were obtained fromSigma-Aldrich (St. Louis,
MO). Recombinant mouse RANKL was purchased from
Koma Biotech (Seoul, Republic of Korea) and recombinant
mouse macrophage-colony stimulating factor (M-CSF) was
obtained from R&D system (Minneapolis, MN). TGF-𝛽 was
purchased from PeproTech (Rocky Hill, NJ). All reagents
used in this study were of analytical grade.
2.2. Cell Culture. Mouse BMMs were isolated from the
tibiae of 4-week-old male ICR mice by Histopaque density
gradient centrifugation as described previously [25]. BMMs
were cultured in 𝛼-MEM containing 10% FBS, 1% antibiotic-
antimycoticmixture, and 30 ng/mL ofM-CSF in a humidified
atmosphere of 5% CO
2
at 37∘C. MDA-MB-231 human breast
cancer cells (Korean Cell Line Bank, Seoul, Republic of
Korea) were grown in DMEM containing 10% FBS and 1%
antibiotic-antimycoticmixture in a humidified atmosphere of
5% CO
2
at 37∘C.
2.3. Cell Viability Assay. BMMs (5 × 104 cells/well) were
cultured in a 96-well plate (NUNC, Roskilde, Denmark) with
𝛼-MEM containing 10% FBS and 30 ng/mL of M-CSF in the
presence of the respective saikosaponins at 1 and 10 𝜇M for
5 days. BMMs were also treated with saikosaponin A or D
at the indicated concentrations for 5 days with replacement
of fresh medium every second day. MDA-MB-231 cells (1 ×
104 cells/well) were seeded into 96-well plates with DMEM
containing 10% FBS and then incubated in serum-free media
with the indicated concentrations of saikosaponin A, saikos-
aponin D, and/or TGF-𝛽 (10 ng/mL) for 24 h. Cell viability
was determined using theMTT assay as described previously
[25] and expressed as percentage of control.
2.4. Osteoclast Formation Assay. BMMs (5 × 104 cells/well)
were cultured in a 96-well plate with the medium containing
10% FBS, M-CSF (30 ng/mL), RANKL (100 ng/mL), and
saikosaponins at 5 𝜇M. In the other experiments, BMMswere
treated with saikosaponin A or D at the indicated concen-
trations. Cultures were fed every 2 days with fresh medium
for 5 days. The cells were stained for tartrate-resistant acid
phosphatase (TRAP) using the Acid Phosphatase Leukocyte
kit (Sigma-Aldrich). The total number of TRAP-positive
multinucleated (≥3 nuclei) cells as osteoclasts per well was
counted.
2.5. Gelatin Zymography and Cathepsin K Assay. BMMs
(2 × 106 cells/well) were seeded in a 6-well culture plate
and incubated in medium containing 10% FBS, M-CSF
(30 ng/mL), RANKL (100 ng/mL), and saikosaponin A or D
at the indicated concentrations for 5 days. Cultures were fed
every 2 days with fresh medium. The conditioned media
were collected and then concentrated by centrifugation in
a centricon centrifugal filter device for 30min at 2,450×g
at 4∘C. The protein concentration in the conditioned media
was determined with BCA protein assay reagents (Pierce,
Rockford, IL). The concentrated culture media (35 𝜇g of
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Figure 1: Chemical structure of saikosaponins. (a) Type I saikosaponins, (b) type II saikosaponins, and (c) type III saikosaponins.
proteins) were subjected to 8% SDS-polyacrylamide poly-
acrylamide gel containing 0.2% (w/v) gelatin, respectively.
After electrophoresis, the gel was washed twice with 2.5%
Triton X-100 for 1 h at room temperature and, subsequently,
incubated for 24 h at 37∘C in a reaction buffer containing
50mM Tris-HCl (pH 7.5), 5mM CaCl
2
, 200mM NaCl, and
0.02% Brij-35. The gel was stained with 0.1% Coomassie
brilliant blue R-250. Clear zones against the blue background
indicated the presence of gelatinolytic activities.
Cathepsin K was detected using the Sensizyme cathepsin
K activity assay kit (Sigma-Aldrich, MO) according to the
manufacturer’s instructions. The concentrated culture media
were added to each well of a 96-well plate coated with cathep-
sin K antibody and incubated for 1 h at room temperature.
After washing with PBS, the wells were incubated with the
reactionmixture for 2 h. Absorbancewasmeasured at 405 nm
and the amount of cathepsin K in the conditioned medium
was calculated as pg/mg protein with a standard curve.
2.6. Pit Formation Assay. BMMs (5 × 104 cells) were seeded
into BiocoatOsteologicMultiTest Slides (BDBiosciences, San
Diego, CA), consisting of submicron synthetic mineralized
calcium phosphate thin films coated with various culture
vessels as described previously [25]. The cells were cultured
in medium with 10% FBS, M-CSF (30 ng/mL), and RANKL
(100 ng/mL) for 5 days and then treated with saikosaponin A
or D at 3 and 5 𝜇M for an additional 11 days. Cultures were
fed every 2 days with fresh medium. The cells were lysed
with 5% sodium hypochlorite solution. The images of the
resorbed pits were obtained under light microscopy (original
magnification, ×100).
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Figure 2: Cytotoxicity of saikosaponins onBMMs. (a) BMMs (5× 104 cells/well) were incubated in𝛼-MEMwith 10%FBS,M-CSF (30 ng/mL),
and each saikosaponin (1 and 10 𝜇M) for 5 days. (b) BMMswere treated with saikosaponin A (SSA) or D (SSD) at the indicated concentrations
for 5 days. Cell viability was determined by MTT assay. The data are expressed as the mean ± SE. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 versus BMMs
without saikosaponins.
2.7. Cell InvasionAssay. The invasive ability of cells was inves-
tigated with a 24-well transwell chamber (Corning Costar,
Cambridge, MA) containing polycarbonate membrane filter
(6.5mm diameter and 8 𝜇m pore size). The lower and upper
surfaces of polycarbonate filter inserts were coated with 0.1%
(w/v) gelatin and 1mg/mL Matrigel (BD Biosciences, Palo
Alto, CA) diluted with medium, respectively. Suspensions
of MDA-MB-231 cell (5 × 104 cells/0.1mL) in serum-free
medium with 0.1% BSA and the indicated concentrations
of saikosaponin A or D were placed in the Matrigel-coated
upper part. The lower chamber was filled with 600𝜇L of
medium containing 1% FBS and the indicated concentrations
of saikosaponinAorD in the absence or presence of 10 ng/mL
TGF-𝛽. After 24 h of incubation, the cells were fixed with
70% methanol and stained with hematoxylin. Noninvaded
cells on the upper surface of membrane were gently wiped off
using a cotton swab, and invaded cells on the lower surface
of membrane were mounted on slides. The stained cells were
counted and photographed (original magnification, ×200)
using a Zeiss Axio imager microscope (Carl Zeiss, Gottingen,
Germany).
2.8. RNA Isolation and Quantitative Real-Time RT-PCR.
MDA-MB-231 cells (5 × 105 cells/dish) were seeded in
60mm culture dishes and exposed to TGF-𝛽 (10 ng/mL) and
saikosaponin A or D at indicated concentrations for 24 h.
Total RNA was isolated from MDA-MB-231 cells using the
RNeasy mini kit (Qiagen, Valencia, CA). RNA was con-
verted to cDNA and then amplified using PrimeScript RT
reagent kit (Takara Bio, Shiga, Japan). Quantitative real-time
PCR analysis was conducted using 7300 Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA). The
thermocycler parameters were 95∘C for 30 sec, followed by 40
cycles of 95∘C for 5 sec and 60∘C for 31 sec. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)was used for normaliza-
tion of mRNA analysis. The cycle threshold (Ct) was defined
as 35 for the ΔCt calculation. Primer sequences are as fol-
lows: PTHrP, GACGACACACGCACTTGAAA (sense) and
GGTTGCTTCCGGAAAGTTG (antisense), and GAPDH,
CATGAGAAGTATGACAACAGCCT (sense) and AGTC-
CTTCCACGATACCAAAGT (antisense).
2.9. Statistical Analysis. Data are expressed as the mean
± standard error (SE) of three independent experiments.
The statistical significance of the difference was analyzed by
repeated measures of one-way analysis of variance followed
by Student’s 𝑡-test. Values of 𝑃 < 0.05 were considered
statistically significant.
3. Results
3.1. Effects of Saikosaponins on the Viability of BMMs. The
cytotoxicity in BMMswhen exposed to the sevenB. falcatum-
derived saikosaponins was determined by the MTT assay.
At 10 𝜇M concentrations, saikosaponins B
1
and C had weak
cytotoxicity (71–79% cell viability) and saikosaponins B
2
, B
3
,
and B
4
did not have any effect on cell viability (Figure 2(a)).
Saikosaponins A and D markedly decreased cell viability
when the cells were exposed to more than 3 𝜇M (Figure 2(b))
with IC
50
values of 5.2 and 5.4 𝜇M, respectively.
3.2. Effects of Saikosaponins on Osteoclast Formation in
RANKL-Treated BMMs. We next investigated the activity of
the saikosaponins on RANKL-induced osteoclastogenesis.
Treatment with saikosaponin A or D at 5𝜇M almost com-
pletely inhibited osteoclast differentiation in BMMs treated
with M-CSF and RANKL for 5 days. Saikosaponins B
4
and
C reduced osteoclast formation by 23 and 17%, respectively;
however, saikosaponins B
1
and B
2
did not show any sig-
nificant inhibition (Figure 3(a)). Furthermore, we confirmed
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Figure 3: Effects of saikosaponins on RANKL-induced osteoclast formation in BMMs. (a) BMMs (5 × 104 cells/well) were cultured in 10%
FBS, 𝛼-MEM with M-CSF (30 ng/mL), RANKL (100 ng/mL), and each saikosaponin (5 𝜇M). (b) BMMs were treated with saikosaponin A
(SSA) or D (SSD) at the indicated concentrations. Control cells were treated with M-CSF alone. Five days later, RANKL-treated BMMs were
stained for TRAP. TRAP-positivemultinucleated (>3 nuclei) cells were photographed (originalmagnification, 100x) and counted.Thenumber
of osteoclasts is expressed as the mean ± SE. #𝑃 < 0.0001 versus control and ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 versus RANKL-treated BMMs.
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that saikosaponins A and D reduced RANKL-induced osteo-
clast formation in a dose-dependent manner (Figure 3(b)).
The IC
50
values for saikosaponins A and D were 3.69 and
3.85 𝜇M, respectively.
3.3. Effects of Saikosaponins A and D on the Formation of
Resorption Pits. Proteases produced by the activated osteo-
clasts were analyzed in the cultured medium of BMMs
treated with RANKL in the presence of saikosaponins for 5
days. Gelatin zymography indicated that RANKL treatment
noticeably increased the levels of pro- and active forms of
matrix metalloproteinase (MMP)-2 and MMP-9; however,
saikosaponin A or D treatment suppressed the RANKL-
induced levels of pro- and activeMMP-9 in a dose-dependent
manner in the conditioned medium of BMMs. The RANKL-
induced level of active MMP-2 was also reduced by these
saikosaponins but that of pro-MMP-2 was not (Figure 4(a)).
Moreover, we found that the significantly increased cathep-
sin K level in the conditioned medium of RANKL-treated
BMMs was dose-dependently inhibited by treatment with
saikosaponin A or D (Figure 4(b)). The inhibitory effect of
saikosaponins A and D on the bone-resorptive activity of
RANKL-induced osteoclasts was determined by the pit for-
mation assay. BMMs were treated with M-CSF and RANKL
for 5 days to induce osteoclast formation and then exposed to
saikosaponin A or D in the presence of M-CSF and RANKL
for 11 days. Treatment with saikosaponin A or D at 3 and
5 𝜇M substantially reduced the formation of resorption pits
compared to the vehicle-treated slides (Figure 4(c)).
3.4. Effects of Saikosaponins A and D on the Viability, Inva-
sion, and PTHrP mRNA Expression in MDA-MB-231 Human
Metastatic Breast Cancer Cells. TGF-𝛽 is very abundant
growth factor in bone and promotes colonization, invasion,
and osteolysis of bone metastases [26]. Saikosaponins A
and D dose-dependently inhibited the viability of MDA-
MB-231 cells (IC
50
= 5.1 𝜇M for saikosaponin A, 2.3 𝜇M for
saikosaponin D). TGF-𝛽 significantly increased cell viability
but TGF-𝛽-induced cell viability was decreased by 22%, 47%,
and 85% by treatment with saikosaponin A at 1, 5, and 10 𝜇M
and by 32% and 80% by treatment with saikosaponin D at 1
and 3 𝜇M, respectively (Figure 5(a)). Treatment with saikos-
aponin A or D at 1 𝜇M significantly reduced the number
of invaded cells in TGF-𝛽-stimulated cells (Figure 5(b)). In
addition, TGF-𝛽 upregulated PTHrP mRNA expression but
saikosaponins A andD significantly reduced TGF-𝛽-induced
PTHrP mRNA expression (Figure 5(c)).
4. Discussion
Bone morphogenesis and remodeling is a physiologically
controlled process that involves the synthesis of bone matrix
by osteoblasts and osteoclast-mediated bone resorption.
Imbalances between osteoclast and osteoblast activities can
arise from a wide variety of hormonal changes or pertur-
bations in inflammatory and growth factors, resulting in
skeletal abnormalities characterized by decreased (osteo-
porosis) or increased (osteopetrosis) bone mass. Increased
osteoclast activity is seen in many osteopenic disorders such
as postmenopausal osteoporosis, Paget’s disease, lytic bone
metastases in breast or prostate cancers, or increased bone
resorption and crippling bone damage in arthritis [26]. The
differentiation of osteoclast precursors into mature multi-
nucleated osteoclasts is stimulated by M-CSF and RANKL
[27]. RANKL, expressed in bone marrow stromal cells and
osteoblasts, is a critical factor to form osteoclasts and binds its
receptor RANK on osteoclast precursor cells. The RANKL-
RANK binding triggers osteoclastogenesis by transducing
a signal into the osteoclast precursors. Therefore, blockade
of the RANKL-induced osteoclastogenesis is a promising
strategy for reversing the onset and progression of osteoclast-
mediated bone diseases. This study was designed to estimate
the potential of saikosaponins as novel agents for preventing
and treating osteoporosis and cancer-associated bone dis-
eases.Of the seven saikosaponins, saikosaponinsA andDhad
the strongest inhibition on osteoclast formation in RANKL-
treated BMMs and substantially blocked the formation of
osteoclast-mediated resorption pits on calcium phosphate-
coated slides. These results suggest that saikosaponins A and
D are potent antiosteoclastogenic and antibone resorptive
agents.
Osteoclast-mediated bone resorption is generated by the
removal of both mineral and organic constituents of the
bone matrix. Osteoclasts produce various proteinases that
efficiently degrade the matrix of bone. The degradation of
organic matrix in bone is principally caused by MMPs and
cathepsin K [28, 29]. MMPs are crucial for launching bone
resorption by eradicating the collagenous layer from bone
surface before starting demineralization [30]. Among several
MMPs, MMP-9 is the most important proteinase involved
in bone resorption as osteoclasts secrete this enzyme at a
tremendously high level [29, 31]. Cathepsin K, a member of
the papain cysteine protease superfamily, is highly expressed
by mature osteoclasts [32]. The overexpressed cathepsin K
stimulates bone resorption by degrading matrix proteins of
bone, such as type I and type II collagen, osteopontin, and
osteonectin, at low pH [32]. Recently, cathepsin K inhibitors
as antiresorptive agents have been tested in clinical trials;
however, this class of drug caused morphea [33, 34]. Our
data indicated that saikosaponin A or D treatment reduced
the levels of MMP-2, MMP-9, and cathepsin K secreted from
RANKL-treated BMMs in a dose-dependent manner. These
results suggest that saikosaponins A and D may inhibit bone
resorption by reducing the secreted levels of MMP-2, MMP-
9, and cathepsin K from mature osteoclasts derived from
RANKL-treated BMMs.
Saikosaponin triterpenes generally constitute the main
class of secondary metabolites in the genus Bupleurum
amounting to up to 7% of the total dry weight in roots [13].
Saikosaponins can be divided into six types on the basis
of the aglycones [19]. In this study, we isolated three types
of saikosaponins: type I (saikosaponins A, D, and C) with
an allyl oxide linkage in the 13, 28-position as the major
saponins present in Bupleurum and maker compounds for
quality control of closely related Bupleurum species, type II
(saikosaponins B
1
and B
2
) with a heteroannular diene struc-
ture, and type III (saikosaponins B
3
and B
4
) with a 11-OCH
3
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Figure 4: Effects of saikosaponins A andD on osteoclasts activity and the formation of resorption pits. BMMs (2 × 106 cells/well) were seeded
into a 6-well culture plate and incubated in a medium containing M-CSF (30 ng/mL), RANKL (100 ng/mL), and saikosaponin A or D for 5
days. Control cells were cultured in the presence ofM-CSF alone.The culturemediumwas collected and concentrated. (a)The levels ofMMP-
2 and MMP-9 in the conditioned medium were determined by gelatin zymography. Relative activity was described as fold by densitometric
analysis. (b) Cathepsin K level was detected with the Sensizym cathepsin K activity assay kit. (c) BMMs (5 × 104 cells/well) were treated
with M-CSF (30 ng/mL), RANKL (100 ng/mL), and the indicated concentrations of saikosaponin A (SSA) or D (SSD) on Biocoat Osteologic
Multitest slides for 11 days after the induction of osteoclast formation. Control cells were treated with M-CSF alone. Cells were lysed and the
pit areas were observed under phase-contrast microscopy. Data are expressed as the mean ± SE. #𝑃 < 0.05 versus control and ∗𝑃 < 0.05 and
∗∗
𝑃 < 0.001 versus RANKL-treated BMMs.
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Figure 5: Effects of saikosaponinsA andDon cell viability, invasion, and PTHrPmRNAexpression inMDA-MB-231metastatic human breast
cancer cells. (a) MDA-MB-231 cells were treated with saikosaponin A, saikosaponin D, and/or TGF-𝛽 (10 ng/mL) for 24 h. Cell viability was
determined by MTT assay. (b) Cell invasion assay was performed using a transwell chamber containing a polycarbonate membrane filter
(6.5mm diameter and 8 𝜇m pore size), coated with 0.1% (w/v) gelatin and Matrigel, as described in Materials and Methods. MDA-MB-231
cell suspensions with the indicated concentrations of saikosaponin A or D were added into the coated insert and the lower chamber was
filled with 600 𝜇L of medium containing 1% FBS, saikosaponin A or D, and TGF-𝛽 (10 ng/mL). Transwell plates were incubated for 24 h.
After hematoxylin staining, the membranes with invaded cells were mounted on slides. (c) PTHrP mRNA expression was determined by
quantitative real-time RT-PCR in MDA-MB-231 cells treated with TGF-𝛽 (10 ng/mL) and saikosaponin A or D at indicated concentrations
for 24 h. GAPDH was used for normalization of mRNA analysis. The gene expression levels are indicated as fold changes. Data are expressed
as mean ± SE. #𝑃 < 0.05 and ##𝑃 < 0.005 versus untreated cells and ∗𝑃 < 0.05 and ∗∗𝑃 < 0.005 versus TGF-𝛽-treated cells.
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[11]. Type I saikosaponins substantially inhibited osteoclast
formation inRANKL-treatedBMMs compared to other types
of saikosaponins. In type I saikosaponins, saikosaponins A
andD,with two carbohydrate chains that are directly attached
to the hydroxyl groups in position 3, showed more potent
inhibition on RANKL-induced osteoclastogenesis compared
to saikosaponin C with three carbohydrate chains. These
results suggest that the potent antibone resorptive activity of
saikosaponins A andD is closely associated with both an allyl
oxide linkage at the 13, 28-position and 𝛽-D-glucose-(1→ 3)-
𝛽-D-fucose at the 3-position; however, the stereochemistry of
the hydroxyl group at C16 does not affect their activity.
In a vicious cycle of breast cancer bone metastasis, many
growth factors and cytokines are released from bone matrix
during osteoclastic bone resorption. These molecules cause
severe bone loss by stimulating tumor growth in bone and
production of tumor-derived osteolytic factors, inducing
osteoblastic RANKL expression [35]. In particular, TGF-
𝛽 increases tumor cell invasiveness and the production of
several osteolytic factors, including PTHrP [36]. Our data
indicated that saikosaponins A and D reduced cell viability
and invasion and upregulated PTHrP mRNA expression in
TGF-𝛽-stimulated MDA-MB-231 metastatic human breast
cancer cells.
5. Conclusion
Saikosaponins A and D inhibited RANKL-mediated osteo-
clast formation in BMMs and osteoclast-induced bone
resorption by reducing the levels of MMP-2, MMP-9,
and cathepsin K at noncytotoxic concentration. In addi-
tion, saikosaponins A and D inhibited TGF-𝛽-induced cell
invasion and PTHrP mRNA expression in MDA-MB-231
metastatic human breast cancer cells. Therefore, saikos-
aponins A andD could be potential therapeutic agents for the
inhibition of osteoclast-mediated bone diseases, including
osteoporosis and cancer cell-related bone loss.
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